While TNM staging remains the primary determinant of prognosis in NPC, intratumoral CD8+ TILs may serve as a complementary biomarker to optimize risk stratification, particularly in patients with locally advanced disease. The gene discussed is CD8A; the disease is nasopharyngeal carcinoma.